EGFR and KRAS mutations in lung parenchyma of subjects with EGFR/KRAS wild-type lung adenocarcinoma

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Chalela Rengifo, Roberto José, 1985-
• dc.contributor.author González-García, José Gregorio
• dc.contributor.author Khilzi, Karys
• dc.contributor.author Curull Serrano, Víctor
• dc.contributor.author Sánchez Font, Albert
• dc.contributor.author Longarón Rozalen, Raquel
• dc.contributor.author Rodrigo Calvo, Maria Teresa
• dc.contributor.author Martín-Ontiyuelo, Clara
• dc.contributor.author Gea Guiral, Joaquim
• dc.contributor.author Bellosillo Paricio, Beatriz
• dc.date.accessioned 2021-10-06T06:57:11Z
• dc.date.available 2021-10-06T06:57:11Z
• dc.date.issued 2021
• dc.description.abstract The acquisition of driver mutations in non-tumoral cells appears to be very important during the carcinogenesis of adenocarcinoma (ADC). Recent studies suggest that cancer-related mutations may not necessarily be present only in malignant cells, but also in histologically "healthy cells". Objective: to demonstrate the presence of EGFR or KRAS mutations in non-tumoral lung cells in subjects with ADC and negative mutational status. Results: mutations in EGFR or KRAS oncogenes were identified in the normal lung in 9.7% of the subjects. Exon 21 substitution L858R in EGFR was detected in two cases while the exon 19 deletion E746-A750 in the EGFR, the G12C and G12D substitutions in the KRAS were detected once. One patient presented three different mutations in the normal lung parenchyma (EGFR_L858R, KRAS_G12C and KRAS_G12D). The negative-mutation status of the tumor and the mutations detected in the "normal lung" were confirmed using highly sensitive and specific TaqMan PCR (CAST-PCR). No differences were found in terms of progression, progression-free survival or overall survival during the 18 months follow-up. Conclusions: These results confirm the presence of driver mutations in the histologically normal lung parenchyma cells in the absence of mutations coexisting with the primary tumor.
• dc.format.mimetype application/pdf
• dc.identifier.citation Chalela R, González-García JG, Khilzi K, Curull V, Sánchez-Font A, Longarón R, Rodrigo-Calvo MT, Martín-Ontiyuelo C, Gea J, Bellosillo B. EGFR and KRAS mutations in lung parenchyma of subjects with EGFR/KRAS wild-type lung adenocarcinoma. Pathol Oncol Res. 2021;27:598292. DOI: 10.3389/pore.2021.598292
• dc.identifier.doi http://dx.doi.org/10.3389/pore.2021.598292
• dc.identifier.issn 1219-4956
• dc.identifier.uri http://hdl.handle.net/10230/48576
• dc.language.iso eng
• dc.publisher Frontiers
• dc.relation.ispartof Pathol Oncol Res. 2021;27:598292
• dc.rights © 2021 Chalela, González-García, Khilzi, Curull, Sánchez-Font, Longarón, Rodrigo-Calvo, Martín-Ontiyuelo, Gea and Bellosillo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword EGFR–epidermal growth factor receptor
• dc.subject.keyword KRAS
• dc.subject.keyword Prognosis
• dc.subject.keyword Adenocacinoma lung
• dc.subject.keyword Driver mutation
• dc.title EGFR and KRAS mutations in lung parenchyma of subjects with EGFR/KRAS wild-type lung adenocarcinoma
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion